Flexion Therapeutics Inc (NASDAQ:FLXN) has been given a $40.00 price target by investment analysts at Cantor Fitzgerald in a research note issued on Thursday, May 4th. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 127.01% from the stock’s previous close.
Several other research firms have also weighed in on FLXN. Wells Fargo & Co reaffirmed an “outperform” rating and set a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 25th. BMO Capital Markets reaffirmed a “positive” rating and set a $33.00 target price on shares of Flexion Therapeutics in a report on Tuesday, February 7th. Janney Montgomery Scott reaffirmed a “buy” rating and set a $30.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 14th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 target price on shares of Flexion Therapeutics in a report on Saturday, March 11th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $29.23.
Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 1.03% during midday trading on Thursday, hitting $17.62. 515,460 shares of the stock traded hands. The firm’s market capitalization is $559.56 million. Flexion Therapeutics has a 52 week low of $10.24 and a 52 week high of $29.41. The company’s 50-day moving average is $22.93 and its 200 day moving average is $20.52.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.02. Analysts anticipate that Flexion Therapeutics will post ($3.72) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Flexion Therapeutics Inc (FLXN) a $40.00 Price Target” was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/05/20/flexion-therapeutics-inc-flxn-given-a-40-00-price-target-by-cantor-fitzgerald-analysts-updated.html.
In other news, insider Neil Bodick sold 5,000 shares of the business’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $28.23, for a total transaction of $141,150.00. Following the transaction, the insider now owns 46,137 shares of the company’s stock, valued at approximately $1,302,447.51. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Frederick W. Driscoll sold 3,000 shares of the business’s stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $23.00, for a total transaction of $69,000.00. Following the transaction, the chief financial officer now directly owns 10,777 shares in the company, valued at approximately $247,871. The disclosure for this sale can be found here. Insiders have sold 18,000 shares of company stock valued at $407,950 in the last ninety days. Insiders own 18.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in FLXN. Keybank National Association OH boosted its position in Flexion Therapeutics by 0.7% in the fourth quarter. Keybank National Association OH now owns 10,357 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 67 shares during the last quarter. SECOR Capital Advisors LP bought a new position in Flexion Therapeutics during the third quarter worth approximately $214,000. Stoneridge Investment Partners LLC bought a new position in Flexion Therapeutics during the third quarter worth approximately $271,000. Monarch Partners Asset Management LLC bought a new position in Flexion Therapeutics during the first quarter worth approximately $279,000. Finally, Asset Management One Co. Ltd. bought a new position in Flexion Therapeutics during the first quarter worth approximately $319,000. 62.25% of the stock is currently owned by hedge funds and other institutional investors.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.